312 related articles for article (PubMed ID: 32159414)
1. Clinical aspects in patients with rheumatoid arthritis complicated with lymphoproliferative disorders without regression after methotrexate withdrawal and treatment for arthritis after regression of lymphoproliferative disorders.
Nakano K; Saito K; Nawata A; Hanami K; Kubo S; Miyagawa I; Fujino Y; Nakayamada S; Tanaka Y
Mod Rheumatol; 2021 Jan; 31(1):94-100. PubMed ID: 32159414
[TBL] [Abstract][Full Text] [Related]
2. Treatment of rheumatoid arthritis after regression of lymphoproliferative disorders in patients treated with methotrexate: a retrospective, multi-center descriptive study.
Nakano K; Tanaka Y; Saito K; Kaneko Y; Saito S; Tanaka M; Saito R; Fujii T; Kuramoto N; Sugimoto N; Takada H; Harigai M; Sasaki S; Suzuki Y
Mod Rheumatol; 2022 Jan; 32(1):41-49. PubMed ID: 33164614
[TBL] [Abstract][Full Text] [Related]
3. Prognostic factors of methotrexate-associated lymphoproliferative disorders associated with rheumatoid arthritis and plausible application of biological agents.
Katsuyama T; Sada KE; Yan M; Zeggar S; Hiramatsu S; Miyawaki Y; Ohashi K; Morishita M; Watanabe H; Katsuyama E; Takano-Narazaki M; Toyota-Tatebe N; Sunahori-Watanabe K; Kawabata T; Miyake K; Kiguchi T; Wada J
Mod Rheumatol; 2017 Sep; 27(5):773-777. PubMed ID: 27846761
[TBL] [Abstract][Full Text] [Related]
4. Distinct decrease in peripheral lymphocytes in EBER-positive cases of MTX-LPD.
Kondo M; Murakawa Y; Moriyama M; Honda M; Sugiura T; Onoda K; Watanabe Y; Kakimaru H
Mod Rheumatol; 2021 Jan; 31(1):88-93. PubMed ID: 32075469
[TBL] [Abstract][Full Text] [Related]
5. Distinct patterns of lymphocyte count transition in lymphoproliferative disorder in patients with rheumatoid arthritis treated with methotrexate.
Saito S; Kaneko Y; Yamaoka K; Tokuhira M; Takeuchi T
Rheumatology (Oxford); 2017 Jun; 56(6):940-946. PubMed ID: 28165538
[TBL] [Abstract][Full Text] [Related]
6. Outcomes of methotrexate-associated lymphoproliferative disorders in rheumatoid arthritis patients treated with disease-modifying anti-rheumatic drugs.
Harada T; Iwasaki H; Muta T; Urata S; Sakamoto A; Kohno K; Takase K; Miyamura T; Sawabe T; Asaoku H; Oryoji K; Fujisaki T; Mori Y; Yoshimoto G; Ayano M; Mitoma H; Miyamoto T; Niiro H; Yamamoto H; Oshiro Y; Miyoshi H; Ohshima K; Takeshita M; Akashi K; Kato K
Br J Haematol; 2021 Jul; 194(1):101-110. PubMed ID: 33822354
[TBL] [Abstract][Full Text] [Related]
7. The clinical impact of absolute lymphocyte count in peripheral blood among patients with methotrexate - associated lymphoproliferative disorders.
Tokuhira M; Tanaka Y; Takahashi Y; Kimura Y; Tomikawa T; Anan T; Watanabe J; Sagawa M; Higashi M; Momose S; Amano K; Tabayashi T; Nakaseko R; Tamaru JI; Kizaki M
J Clin Exp Hematop; 2020 Jun; 60(2):41-50. PubMed ID: 32404570
[TBL] [Abstract][Full Text] [Related]
8. Methotrexate-associated Lymphoproliferative Disorders in Patients With Rheumatoid Arthritis: Clinicopathologic Features and Prognostic Factors.
Kurita D; Miyoshi H; Ichikawa A; Kato K; Imaizumi Y; Seki R; Sato K; Sasaki Y; Kawamoto K; Shimono J; Yamada K; Muto R; Kizaki M; Nagafuji K; Tamaru JI; Tokuhira M; Ohshima K
Am J Surg Pathol; 2019 Jul; 43(7):869-884. PubMed ID: 31116708
[TBL] [Abstract][Full Text] [Related]
9. Lymphoproliferative disorder risk after methotrexate treatment for rheumatoid arthritis.
Tanaka K; Ichikawa A; Umezawa N; Yamamoto K; Yoshifuji K; Okada K; Nogami A; Umezawa Y; Nagao T; Sakashita C; Mori T; Tohda S; Koike R; Yasuda S; Yamamoto M
Cancer Sci; 2023 Sep; 114(9):3719-3727. PubMed ID: 37365854
[TBL] [Abstract][Full Text] [Related]
10. Clinical characteristics and incidence of methotrexate-related lymphoproliferative disorders of patients with rheumatoid arthritis.
Yoshida Y; Takahashi Y; Yamashita H; Kano T; Kaneko H; Mimori A
Mod Rheumatol; 2014 Sep; 24(5):763-5. PubMed ID: 24498893
[TBL] [Abstract][Full Text] [Related]
11. [Methotrexate-associated lymphoproliferative disorders: clinical aspects].
Tokuhira M; Kizaki M
Rinsho Ketsueki; 2019; 60(8):932-943. PubMed ID: 31484893
[TBL] [Abstract][Full Text] [Related]
12. Clinical characteristics of methotrexate-associated lymphoproliferative disorders: relationship between absolute lymphocyte count recovery and spontaneous regression.
Takanashi S; Aisa Y; Ito C; Arakaki H; Osada Y; Amano Y; Hirano M; Nakazato T
Rheumatol Int; 2017 Oct; 37(10):1629-1633. PubMed ID: 28676912
[TBL] [Abstract][Full Text] [Related]
13. Effect of Recent Antirheumatic Drug on Features of Rheumatoid Arthritis-Associated Lymphoproliferative Disorders.
Hoshida Y; Tsujii A; Ohshima S; Saeki Y; Yagita M; Miyamura T; Katayama M; Kawasaki T; Hiramatsu Y; Oshima H; Murayama T; Higa S; Kuraoka K; Hirano F; Ichikawa K; Kurosawa M; Suzuki H; Chiba N; Sugiyama T; Minami Y; Niino H; Ihata A; Saito I; Mitsuo A; Maejima T; Kawashima A; Tsutani H; Takahi K; Kasai T; Shinno Y; Tachiyama Y; Teramoto N; Taguchi K; Naito S; Yoshizawa S; Ito M; Suenaga Y; Mori S; Nagakura S; Yoshikawa N; Nomoto M; Ueda A; Nagaoka S; Tsuura Y; Setoguchi K; Sugii S; Abe A; Sugaya T; Sugahara H; Fujita S; Kunugiza Y; Iizuka N; Yoshihara R; Yabe H; Fujisaki T; Morii E; Takeshita M; Sato M; Saito K; Matsui K; Tomita Y; Furukawa H; Tohma S
Arthritis Rheumatol; 2024 Jun; 76(6):869-881. PubMed ID: 38272827
[TBL] [Abstract][Full Text] [Related]
14. Association of higher methotrexate dose with lymphoproliferative disease onset in rheumatoid arthritis patients.
Kameda T; Dobashi H; Miyatake N; Inoo M; Onishi I; Kurata N; Mitsunaka H; Kawakami K; Fukumoto T; Susaki K; Izumikawa M; Nakashima S; Shimada H; Takeuchi Y; Haba R; Mano S; Onishi H; Imataki O; Matsunaga T
Arthritis Care Res (Hoboken); 2014 Sep; 66(9):1302-9. PubMed ID: 24515570
[TBL] [Abstract][Full Text] [Related]
15. Lymphoproliferative disorders in patients with rheumatoid arthritis in the era of widespread use of methotrexate: A review of the literature and current perspective.
Harigai M
Mod Rheumatol; 2018 Jan; 28(1):1-8. PubMed ID: 28758827
[TBL] [Abstract][Full Text] [Related]
16. Lymphoproliferative disorders in rheumatoid arthritis: clinicopathological analysis of 76 cases in relation to methotrexate medication.
Hoshida Y; Xu JX; Fujita S; Nakamichi I; Ikeda J; Tomita Y; Nakatsuka S; Tamaru J; Iizuka A; Takeuchi T; Aozasa K
J Rheumatol; 2007 Feb; 34(2):322-31. PubMed ID: 17117491
[TBL] [Abstract][Full Text] [Related]
17. Characteristics and risk factors of lymphoproliferative disorders among patients with rheumatoid arthritis concurrently treated with methotrexate: a nested case-control study of the IORRA cohort.
Shimizu Y; Nakajima A; Inoue E; Shidara K; Sugimoto N; Seto Y; Tanaka E; Momohara S; Taniguchi A; Yamanaka H
Clin Rheumatol; 2017 Jun; 36(6):1237-1245. PubMed ID: 28455827
[TBL] [Abstract][Full Text] [Related]
18. Methotrexate-associated orbital lymphoproliferative disorder in a patient with rheumatoid arthritis: a case report.
Kobayashi Y; Kimura K; Fujitsu Y; Shinkawa K; Muta H; Sonoda KH
Jpn J Ophthalmol; 2016 May; 60(3):212-8. PubMed ID: 27018050
[TBL] [Abstract][Full Text] [Related]
19. Methotrexate/iatrogenic lymphoproliferative disorders in rheumatoid arthritis: histology, Epstein-Barr virus, and clonality are important predictors of disease progression and regression.
Ichikawa A; Arakawa F; Kiyasu J; Sato K; Miyoshi H; Niino D; Kimura Y; Takeuchi M; Yoshida M; Ishibashi Y; Nakashima S; Sugita Y; Miura O; Ohshima K
Eur J Haematol; 2013 Jul; 91(1):20-8. PubMed ID: 23560463
[TBL] [Abstract][Full Text] [Related]
20. Methotrexate-associated lymphoproliferative disorder in the stomach and duodenum: a case report.
Toyonaga H; Fukushima M; Shimeno N; Inokuma T
BMC Gastroenterol; 2019 Apr; 19(1):62. PubMed ID: 31023238
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
